My watch list
my.chemeurope.com  
Login  

21 Current news

rss

image description
Caltech researchers develop nanoscale structures with superior mechanical properties

12-Feb-2010

, by Dongchan Jang, senior postdoctoral scholar, and Julia R. Greer, assistant professor of materials science and mechanics at Caltech, could eventually lead to the development of innovative, superstrong, yet...

more

Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer

31-Dec-2001

clinical oncology program with the start of this third Phase II trial for ABX-EGF,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``Our goal is to provide effective, antibody...

more

Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer

28-Dec-2001

clinical oncology program with the start of this third Phase II trial for ABX-EGF," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "Our goal is to provide effective, antibody...

more

Abgenix Introduces Enhanced Version of XenoMouse Technology

05-Dec-2001

. ``The generation of these new strains of XenoMouse mice demonstrates our commitment to maintaining technological leadership in the antibody field,'' said R. Scott Greer, chairman and CEO of Abgenix. ``Our...

more

Abgenix Acquires Rights To Novel Cancer Target

27-Nov-2001

specific antibody treatments for cancer,” said R. Scott Greer, chairman and chief executive officer of Abgenix. “We continue to believe that the epidermal growth factor receptor family offers some...

more

Abgenix Announces CEO Succession Plan

Ray Withy to Become CEO in Mid-2000

20-Nov-2001

FREMONT, Calif., November 19, 2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today plans for Raymond Withy, Ph.D., to succeed R. Scott Greer as the company?s chief executive officer effective in mid...

more

Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer

15-Aug-2001

the collaboration. "We are excited to enter this alliance with Agensys to generate fully human antibody candidates to their large portfolio of novel, clinically relevant cancer antigens," stated R. Scott Greer...

more

Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Non-Small Cell Lung Cancer

01-Aug-2001

with the second Phase II trial this year for ABX-EGF," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "We are pleased with the progress the joint development team has made in advancing...

more

Abgenix Reaches Milestone In Antibody Collaboration With Amgen,

11-Jul-2001

derived from Abgenix technology are in human clinical trials, including two of our own," said R. Scott Greer, chairman and chief executive officer of Abgenix. "We believe our fully human antibody platform...

more

MDS Proteomics And Abgenix Announce Exclusive Agreement To Develop Proteomic-Based Antibody Therapies,

09-Jul-2001

, in a large-scale effort to help change the nature of the drug development process," said R. Scott Greer, chairman and chief executive officer of Abgenix. "With MDS Proteomics’ ability to drill down into each...

more

Page 1 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE